论文部分内容阅读
目的:观察Ⅱ、Ⅲ期结直肠癌患者术后辅以卡培他滨+奥沙利铂(XELOX)方案及替吉奥+奥沙利铂方案的疗效。方法:将128例中晚期结直肠癌术后患者分为试验组和对照组,试验组55例给予奥沙利铂联合替吉奥胶囊,每3周为1周期;对照组73例给予奥沙利铂联合卡培他滨进行化疗,每3周为1周期。采用美国国立癌症研究所常见不良事件评价标准进行评定。结果:试验组6个月生存率(96.4%)低于对照组(98.6%),试验组9、12个月生存率(92.7%、89.1%)高于对照组(91.8%、86.3%),两组比较差异无统计学意义(P>0.05);两组不良反应主要为骨髓抑制(白细胞、血小板、血红蛋白计数下降),胃肠道反应(恶心、呕吐、腹泻)、末梢神经毒性、肝功能损伤、脱发,不良反应主要表现为Ⅰ-Ⅱ级,Ⅲ-Ⅳ级较少见。结论:Ⅱ、Ⅲ期结直肠癌患者术后辅以替吉奥联合奥沙利铂方案与卡培他滨联合奥沙利铂(XELOX)方案其疗效及不良反应无明显差异。
OBJECTIVE: To observe the effect of postoperative capecitabine + oxaliplatin (XELOX) regimen and tegaserod + oxaliplatin regimen in patients with stage Ⅱ and Ⅲ colorectal cancer. Methods: 128 patients with advanced colorectal cancer were divided into experimental group and control group. The experimental group was given oxaliplatin combined with getinib capsule every three weeks for one week and the control group was given Osage Platinum plus capecitabine for chemotherapy, 1 cycle every 3 weeks. Using the National Institutes of Health common adverse event evaluation criteria for evaluation. Results: The 6-month survival rate (96.4%) in the experimental group was lower than that in the control group (98.6%). The survival rates at 9 and 12 months in the experimental group were 92.7% and 89.1% higher than those in the control group (91.8% and 86.3% There was no significant difference between the two groups (P> 0.05). Adverse reactions of the two groups mainly included myelosuppression (white blood cell count, platelet count, hemoglobin count decrease), gastrointestinal reaction (nausea, vomiting and diarrhea), peripheral neurotoxicity , Hair loss, adverse reactions mainly as Ⅰ-Ⅱ level, Ⅲ-Ⅳ level less common. CONCLUSION: There is no significant difference in the curative effect and adverse reactions of patients with stage Ⅱ and Ⅲ colorectal cancer after adjuvant with tegaserod combined oxaliplatin and capecitabine plus oxaliplatin (XELOX).